Mirum initiates enrolment in Phase IIb VISTAS study of volixibat for PSC
Mirum Pharmaceuticals has enrolled the first patient in its Phase IIb VISTAS study of volixibat in adult patients with primary…
15 Jan 2021
Knopp Biosciences reports positive trial results of oral asthma drug
Drug discovery and development firm Knopp Biosciences has announced positive top-line results from a Phase II dose-ranging trial of a novel oral drug, dexpramipexole, in patients with moderate-to-severe eosinophilic asthma.…
15 Jan 2021
Ampio completes 55% patient enrolment in Covid-19 trial
Biopharmaceutical firm Ampio Pharmaceuticals has announced the enrolment of 55% of the participants in its ongoing US Phase I clinical trial of inhalation treatment Ampion (AP-014) for patients with respiratory…
13 Jan 2021
Terns concludes patient enrolment in NASH treatment trial
Clinical-stage biopharmaceutical firm Terns Pharmaceuticals has completed patient enrolment in Phase IIa LIFT study of TERN-101 for treating non-alcoholic steatohepatitis (NASH) patients. A liver-distributed non-bile acid farnesoid X receptor (FXR)…
13 Jan 2021
Celltrion’s Covid-19 drug shows therapeutic efficacy in Phase II trials
South Korean company Celltrion has reported data from Phase II clinical trials confirming that its Covid-19 treatment candidate, Regkirona (CT-P59; regdanvimab), demonstrated better therapeutic efficacy than other antibody treatments. Korea…
13 Jan 2021
GSK and Vir Biotechnology to initiate NHS-backed Covid-19 trial
GlaxoSmithKline (GSK) and Vir Biotechnology have announced an agreement with the UK-based AGILE initiative to conduct Phase Ib/IIa clinical trial of a monoclonal antibody, VIR-7832, in mild to moderate Covid-19…
12 Jan 2021
Lilly reports positive data from Alzheimer’s disease treatment trial
Eli Lilly and Company has reported that data from Phase II TRAILBLAZER-ALZ study of its investigational antibody, donanemab, showed a significant slowing of decline in patients with early symptomatic Alzheimer's…